HOME >> MEDICINE >> NEWS
Protein identified that may play central role in inflammatory bowel disease

CHARLOTTESVILLE, Va., Nov. 10 Researchers at the University of Virginia Health System have discovered that a protein expressed by the immune system, called TL1A, is linked to inflammatory bowel disease (IBD) in patients, especially Crohn's disease. This is the first time TL1A has been linked to Crohn's. In a study involving fifty patients at U.Va., published in the Nov. 1 issue of The Journal of Immunology, the research team found that TL1A was expressed in patients suffering from IBD, but not in control patients who are disease free. The finding could lead to new treatments for people who suffer from IBD, the general name for two diseases that cause inflammation in the intestines.

Ulcerative colitis causes inflammation and ulcers in the top layer of the intestinal lining, usually in the lower part of the large intestine, while in Crohn's, the inflammation extends deep into the lining, usually in the small intestine. Over one million adults and children in the U.S. suffer from inflammatory bowel disease, with about 30,000 new cases diagnosed each year, according to the Crohn's and Colitis Foundation of America. Adolescents and young adults are most susceptible to IBD and there is no cure.

"What we have discovered here at U.Va. is a cytokine, a key protein that regulates the immune response, that could be an important target for therapy in IBD patients who are not responding to current treatments for ulcerative colitis and Crohn's disease," said Dr. Fabio Cominelli, principal investigator of the study, professor of internal medicine and microbiology and director of the Digestive Health Center of Excellence at U.Va. "Blocking the interaction between TL1A and its receptor in the immune response, called DR3, could be beneficial to the thousands of people suffering from chronic intestinal inflammation."

TL1A is a newly discovered member of the tumor necrosis factor (TNF) family of proteins thought to be expressed primarily in the e
'"/>

Contact: Bob Beard
reb8e@virginia.edu
434-982-4490
University of Virginia Health System
10-Nov-2003


Page: 1 2

Related medicine news :

1. Protein that helps skin cancer spread identified by Stanford researchers
2. Proteins found in urine of pregnant women could help diagnose preeclampsia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Protein key could aid search for cancer drugs
5. Lab study: Protein delivered via genetically engineered virus slowed glioblasoma multiforme growth
6. Protein not only aids nerve development, but promotes blood vessel growth, too
7. Protein marker predicts possible heart damage after chemotherapy
8. Protein promotes cancer metastasis and survival
9. Protein helps immune system mount instant strike against deadly flu viruses
10. Protein that predicts tamoxifen resistance is identified
11. Protein implicated in decline of aging hearts

Post Your Comments:
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , Dallas ... Department of Plastic Surgery at UT Southwestern Medical Center, ... blindness resulting from the use of facial aesthetic ... study, along with ideas for treatment and prevention in ... to see increasing reports of blindness as a result ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 2015 Skin cancer is one of the ... caught early. Forefront Dermatology and Dermatology Associates of Wisconsin want ... before it spreads so they are hosting a free skin ... 8:30am - 12:30pm. , “If we can see the ... concern, that could become cancerous,” said Dr. Ken Katz, who ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, ... Inc. (NYSE: VRX and ... completed the previously announced acquisition of ... a specialty pharmaceutical company that offers ...  (rifaximin) 550 mg, RUCONEST ®  (C1 esterase inhibitor ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
Cached News: